O Keefe Stevens Advisory Inc. Has $2.54 Million Stock Holdings in Pfizer Inc. (NYSE:PFE)

O Keefe Stevens Advisory Inc. grew its stake in shares of Pfizer Inc. (NYSE:PFE) by 47.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 95,878 shares of the biopharmaceutical company’s stock after acquiring an additional 31,010 shares during the period. Pfizer accounts for 0.8% of O Keefe Stevens Advisory Inc.’s holdings, making the stock its 26th largest position. O Keefe Stevens Advisory Inc.’s holdings in Pfizer were worth $2,544,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently made changes to their positions in the company. WCG Wealth Advisors LLC raised its position in Pfizer by 15.3% during the second quarter. WCG Wealth Advisors LLC now owns 32,347 shares of the biopharmaceutical company’s stock valued at $905,000 after purchasing an additional 4,295 shares in the last quarter. XTX Topco Ltd boosted its stake in Pfizer by 206.9% in the second quarter. XTX Topco Ltd now owns 73,946 shares of the biopharmaceutical company’s stock valued at $2,069,000 after buying an additional 49,851 shares in the last quarter. ProVise Management Group LLC grew its position in Pfizer by 1.7% in the second quarter. ProVise Management Group LLC now owns 128,926 shares of the biopharmaceutical company’s stock valued at $3,607,000 after acquiring an additional 2,131 shares during the last quarter. Cowa LLC bought a new position in shares of Pfizer in the second quarter worth about $232,000. Finally, Intech Investment Management LLC grew its holdings in shares of Pfizer by 30.3% during the 2nd quarter. Intech Investment Management LLC now owns 725,663 shares of the biopharmaceutical company’s stock valued at $20,304,000 after purchasing an additional 168,724 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

NYSE:PFE opened at $26.30 on Friday. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54. The stock has a market cap of $149.06 billion, a P/E ratio of 35.55, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64. The firm’s fifty day simple moving average is $26.09 and its 200 day simple moving average is $28.00.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. The firm had revenue of $17.70 billion for the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The business’s revenue for the quarter was up 31.2% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.17) EPS. As a group, research analysts predict that Pfizer Inc. will post 2.94 EPS for the current year.

Pfizer Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.54%. The ex-dividend date of this dividend is Friday, January 24th. This is an increase from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio is currently 227.03%.

Analyst Ratings Changes

PFE has been the topic of a number of research reports. Guggenheim decreased their target price on shares of Pfizer from $35.00 to $33.00 and set a “buy” rating on the stock in a research note on Wednesday, December 11th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research note on Wednesday, October 23rd. Sanford C. Bernstein assumed coverage on shares of Pfizer in a research report on Thursday, October 17th. They set a “market perform” rating and a $32.00 target price on the stock. StockNews.com lowered Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. Finally, UBS Group decreased their price target on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research note on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, Pfizer presently has a consensus rating of “Moderate Buy” and an average price target of $32.00.

Insider Activity

In related news, Director Scott Gottlieb acquired 1,000 shares of the stock in a transaction that occurred on Wednesday, October 30th. The shares were bought at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the transaction, the director now directly owns 10,000 shares in the company, valued at approximately $282,400. This trade represents a 11.11 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.06% of the company’s stock.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.